NCT01344564

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide

Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Urology of Virginia · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without a rise in serum testosterone. The investigators expect testosterone will quickly and reliably reach castrate levels after initiation of ADT and will remain castrate during the transition, and there will be no "testosterone surge" after leuprolide injection.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Degarelix acetate, Leuprolide acetate	Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once

Timeline

• Start date: 2011-04-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2011-04-29
• Last updated: 2013-03-18

Locations

1 site across 1 country: United States